Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece. Issue 14 (31st March 2023)
- Record Type:
- Journal Article
- Title:
- Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece. Issue 14 (31st March 2023)
- Main Title:
- Effectiveness of full (booster) COVID-19 vaccination against severe outcomes and work absenteeism in hospitalized patients with COVID-19 during the Delta and Omicron waves in Greece
- Authors:
- Maltezou, Helena C.
Basoulis, Dimitrios
Bonelis, Konstantinos
Gamaletsou, Maria N.
Giannouchos, Theodoros V.
Karantoni, Eleni
Karapanou, Αmalia
Kounouklas, Konstantinos
Livanou, Maria Effrosyni
Zotou, Maria
Rapti, Vasiliki
Stamou, Panagiota
Loulakis, Dimitrios
Souliotis, Kyriakos
Chini, Maria
Panagopoulos, Periklis
Poulakou, Garyfalia
Syrigos, Konstantinos N.
Hatzigeorgiou, Dimitrios
Sipsas, Nikolaos V. - Abstract:
- Abstract: Aim: We estimated vaccine effectiveness (VE) of full (booster) vaccination against severe outcomes in hospitalized COVID-19 patients during the Delta and Omicron waves. Methods: The study extended from November 15, 2021 to April 17, 2022. Full vaccination was defined as a primary vaccination plus a booster ≥ 6 months later. Results: We studied 1138 patients (mean age: 66.6 years), of whom 826 (72.6 %) had ≥ 1 comorbidity. Of the 1138 patients, 75 (6.6 %) were admitted to intensive care unit (ICU), 64 (5.6 %) received mechanical ventilation, and 172 (15.1 %) died. There were 386 (33.9 %) fully vaccinated, 172 (15.1 %) partially vaccinated, and 580 (51 %) unvaccinated patients. Unvaccinated patients were absent from work for longer periods compared to partially or fully vaccinated patients (mean absence of 20.1 days versus 12.3 and 17.3 days, respectively; p-value = 0.03). Compared to unvaccinated patients, fully vaccinated patients were less likely to be admitted to ICU [adjusted relative risk (ARR: 0.49; 95 % CI: 0.29–0.84)], mechanically ventilated (ARR: 0.43; 95 % CI: 0.23–0.80), and die (ARR: 0.57; 95 % CI: 0.42–0.78), while they were hospitalized for significantly shorter periods (ARR: 0.79; 95 % CI: 0.70–0.89). The adjusted full VE was 48.8 % (95 % CI: 42.7 %-54.9 %) against ICU admission, 55.4 % (95 % CI: 52.0 %-56.2 %) against mechanical ventilation, and 22.6 % (95 % CI: 7.4 %-34.8 %) against death. For patients with ≥ 3 comorbidities, VE was 56.2 % (95 %Abstract: Aim: We estimated vaccine effectiveness (VE) of full (booster) vaccination against severe outcomes in hospitalized COVID-19 patients during the Delta and Omicron waves. Methods: The study extended from November 15, 2021 to April 17, 2022. Full vaccination was defined as a primary vaccination plus a booster ≥ 6 months later. Results: We studied 1138 patients (mean age: 66.6 years), of whom 826 (72.6 %) had ≥ 1 comorbidity. Of the 1138 patients, 75 (6.6 %) were admitted to intensive care unit (ICU), 64 (5.6 %) received mechanical ventilation, and 172 (15.1 %) died. There were 386 (33.9 %) fully vaccinated, 172 (15.1 %) partially vaccinated, and 580 (51 %) unvaccinated patients. Unvaccinated patients were absent from work for longer periods compared to partially or fully vaccinated patients (mean absence of 20.1 days versus 12.3 and 17.3 days, respectively; p-value = 0.03). Compared to unvaccinated patients, fully vaccinated patients were less likely to be admitted to ICU [adjusted relative risk (ARR: 0.49; 95 % CI: 0.29–0.84)], mechanically ventilated (ARR: 0.43; 95 % CI: 0.23–0.80), and die (ARR: 0.57; 95 % CI: 0.42–0.78), while they were hospitalized for significantly shorter periods (ARR: 0.79; 95 % CI: 0.70–0.89). The adjusted full VE was 48.8 % (95 % CI: 42.7 %-54.9 %) against ICU admission, 55.4 % (95 % CI: 52.0 %-56.2 %) against mechanical ventilation, and 22.6 % (95 % CI: 7.4 %-34.8 %) against death. For patients with ≥ 3 comorbidities, VE was 56.2 % (95 % CI: 43.9 %-67.1 %) against ICU admission, 60.2 % (95 % CI: 53.7 %-65.4 %) against mechanical ventilation, and 43.9 % (95 % CI: 19.9 %-59.7 %) against death. Conclusions: Full (booster) COVID-19 vaccination conferred protection against severe outcomes, prolonged hospitalization, and prolonged work absenteeism. … (more)
- Is Part Of:
- Vaccine. Volume 41:Issue 14(2023)
- Journal:
- Vaccine
- Issue:
- Volume 41:Issue 14(2023)
- Issue Display:
- Volume 41, Issue 14 (2023)
- Year:
- 2023
- Volume:
- 41
- Issue:
- 14
- Issue Sort Value:
- 2023-0041-0014-0000
- Page Start:
- 2343
- Page End:
- 2348
- Publication Date:
- 2023-03-31
- Subjects:
- COVID-19 -- Booster -- Vaccine effectiveness -- Hospitalization -- Absenteeism
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2023.01.067 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26869.xml